• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 284 例患者的回顾性分析:建立包含颅外转移特征的乳腺癌脑转移患者预后分级评估体系。

Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients.

机构信息

Department of Medical Oncology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.

Department of Medical Records, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.

出版信息

BMC Cancer. 2024 Oct 10;24(1):1262. doi: 10.1186/s12885-024-12983-3.

DOI:10.1186/s12885-024-12983-3
PMID:39390441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11465582/
Abstract

BACKGROUND

Breast cancer brain metastasis (BCBM) is associated with poor survival outcomes and reduced quality of life. The Graded Prognostic Assessment (GPA) score model serves as a well-established tool for predicting the prognosis of BCBM. Notably, the presence of extracranial metastasis (ECM) is considered as a significant prognostic factor in the breast GPA model. This study aims to further refine other features of ECM to enhance the prognostic prediction for BCBM.

METHODS

This study included all inpatients diagnosed with BCBM at the Cancer Hospital, Chinese Academy of Medical Sciences, from January 2010 to July 2021. Baseline characteristics of patients were compared based on features of ECM, including the presence, number, location, and control status of metastases. Overall survival (OS) were compared using the Kaplan-Meier method with log-rank tests. Cox regression analyses were conducted to identify significant prognostic factors. The aforementioned ECM features were incorporated into the original Breast-GPA model to enhance its prognostic accuracy. The concordance index (C-index) and restricted mean survival time (RMST) were utilized to evaluate and compare the predictive accuracy of the updated and original survival models.

RESULTS

284 patients with BCBM were included in the study. Kaplan-Meier survival curves suggested that patients without ECM when diagnosed with BCBM showed better survival (p = 0.007). In the subgroups with ECM, more than 3 organs involved, both bone and visceral metastasis and progressive ECM portended dismal OS (p = 0.003, 0.001 and <0.001). Multivariate analysis demonstrated that molecular subtype, presence of ECM, and number of brain metastasis significantly influenced OS after BCBM. By modifying the current GPA model to include more precise characteristics of ECM, the predictive accuracy was further enhanced as indicated by the C-index and RMST curve.

CONCLUSIONS

More ECM sites, both bone and visceral invasion and uncontrolled ECM were dismal prognostic factors for survival outcomes of BCBM patients. A new Breast-GPA model with better predictive effect was constructed.

摘要

背景

乳腺癌脑转移(BCBM)与不良预后和生活质量下降有关。分级预后评估(GPA)评分模型是预测 BCBM 预后的一种成熟工具。值得注意的是,颅外转移(ECM)的存在被认为是乳腺 GPA 模型中的一个重要预后因素。本研究旨在进一步细化 ECM 的其他特征,以提高对 BCBM 的预后预测。

方法

本研究纳入 2010 年 1 月至 2021 年 7 月在中国医学科学院肿瘤医院住院诊断为 BCBM 的所有患者。根据 ECM 的特征,比较患者的基线特征,包括转移的存在、数量、位置和控制情况。采用 Kaplan-Meier 法和对数秩检验比较总生存期(OS)。采用 Cox 回归分析确定显著的预后因素。将上述 ECM 特征纳入原始乳腺-GPA 模型,以提高其预后准确性。采用一致性指数(C-index)和限制性平均生存时间(RMST)评估和比较更新和原始生存模型的预测准确性。

结果

本研究纳入 284 例 BCBM 患者。Kaplan-Meier 生存曲线表明,诊断为 BCBM 时无 ECM 的患者生存更好(p=0.007)。在 ECM 亚组中,有 3 个以上器官受累、同时有骨和内脏转移以及进展性 ECM 的患者 OS 较差(p=0.003、0.001 和 <0.001)。多变量分析表明,分子亚型、ECM 的存在和脑转移的数量显著影响 BCBM 后的 OS。通过在当前 GPA 模型中加入更精确的 ECM 特征,C-index 和 RMST 曲线表明预测准确性进一步提高。

结论

更多的 ECM 部位、骨和内脏侵犯以及不受控制的 ECM 是 BCBM 患者生存结果的不良预后因素。构建了一种具有更好预测效果的新型乳腺-GPA 模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba4c/11465582/15a3c68cf62a/12885_2024_12983_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba4c/11465582/d1e2e377d9ed/12885_2024_12983_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba4c/11465582/8b953a3f504a/12885_2024_12983_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba4c/11465582/15a3c68cf62a/12885_2024_12983_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba4c/11465582/d1e2e377d9ed/12885_2024_12983_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba4c/11465582/8b953a3f504a/12885_2024_12983_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba4c/11465582/15a3c68cf62a/12885_2024_12983_Fig3_HTML.jpg

相似文献

1
Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients.基于 284 例患者的回顾性分析:建立包含颅外转移特征的乳腺癌脑转移患者预后分级评估体系。
BMC Cancer. 2024 Oct 10;24(1):1262. doi: 10.1186/s12885-024-12983-3.
2
Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today.超越更新后的分级预后评估(乳腺癌 GPA):从 1985 年至今乳腺癌脑转移的预后指数及治疗和生存趋势。
Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):334-343. doi: 10.1016/j.ijrobp.2020.01.051. Epub 2020 Feb 19.
3
A nomogram for predicting survival in patients with breast cancer brain metastasis.一种用于预测乳腺癌脑转移患者生存率的列线图。
Oncol Lett. 2018 May;15(5):7090-7096. doi: 10.3892/ol.2018.8259. Epub 2018 Mar 14.
4
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases.改良版乳腺癌分级预后评估作为乳腺癌合并脑转移患者生存工具的验证与开发
J Clin Oncol. 2015 Jul 10;33(20):2239-45. doi: 10.1200/JCO.2014.58.8517. Epub 2015 May 18.
5
Nomogram-Predicted Survival of Breast Cancer Brain Metastasis: a SEER-Based Population Study.基于 SEER 的人群研究:列线图预测乳腺癌脑转移的生存。
World Neurosurg. 2019 Aug;128:e823-e834. doi: 10.1016/j.wneu.2019.04.262. Epub 2019 May 13.
6
Clinico-pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis.初诊脑转移乳腺癌患者的临床病理因素与生存:国家癌症数据库分析。
Breast Cancer Res Treat. 2024 Aug;206(3):527-541. doi: 10.1007/s10549-024-07321-x. Epub 2024 Apr 29.
7
Validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: extra-cranial disease progression is an independent risk factor.改良版乳腺癌分级预后评估在脑转移乳腺癌患者中的验证:颅外疾病进展是一个独立危险因素。
Ann Palliat Med. 2019 Sep;8(4):390-400. doi: 10.21037/apm.2019.02.05. Epub 2019 Mar 8.
8
Novel models by machine learning to predict prognosis of breast cancer brain metastases.基于机器学习的新型模型预测乳腺癌脑转移的预后。
J Transl Med. 2023 Jun 21;21(1):404. doi: 10.1186/s12967-023-04277-2.
9
Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes.脑转移或软脑膜疾病的乳腺癌患者:全国队列的 10 年结果和预后指标的验证。
Breast J. 2019 Nov;25(6):1117-1125. doi: 10.1111/tbj.13433. Epub 2019 Jul 8.
10
Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.新型靶向治疗时代下 HER2 阳性乳腺癌脑转移自然史的改变
Clin Breast Cancer. 2018 Feb;18(1):29-37. doi: 10.1016/j.clbc.2017.07.017. Epub 2017 Aug 9.

引用本文的文献

1
Multicenter Development of a Clinical-Molecular Nomogram for Predicting Survival in Lung Cancer Brain Metastasis Patients.用于预测肺癌脑转移患者生存情况的临床分子列线图的多中心研发
Cancer Manag Res. 2025 Sep 3;17:1881-1895. doi: 10.2147/CMAR.S538752. eCollection 2025.

本文引用的文献

1
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.曲妥珠单抗 deruxtecan 对比曲妥珠单抗 emtansine 用于治疗 HER2 阳性转移性乳腺癌:DESTINY-Breast03 试验的长期生存分析。
Nat Med. 2024 Aug;30(8):2208-2215. doi: 10.1038/s41591-024-03021-7. Epub 2024 Jun 2.
2
Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer.开发和外部验证转移性乳腺癌患者脑转移预测模型。
J Cancer Res Clin Oncol. 2023 Oct;149(13):12333-12353. doi: 10.1007/s00432-023-05125-y. Epub 2023 Jul 11.
3
Optimizing treatment of brain metastases in an era of novel systemic treatments: a single center consecutive series.
优化新型全身治疗时代的脑转移瘤治疗:单中心连续系列。
J Neurooncol. 2023 Jun;163(2):345-354. doi: 10.1007/s11060-023-04343-1. Epub 2023 Jun 2.
4
Predicting survival and prognosis of postoperative breast cancer brain metastasis: a population-based retrospective analysis.预测乳腺癌脑转移术后的生存和预后:基于人群的回顾性分析。
Chin Med J (Engl). 2023 Jul 20;136(14):1699-1707. doi: 10.1097/CM9.0000000000002674. Epub 2023 May 31.
5
Prognosis prediction and risk factors for triple-negative breast cancer patients with brain metastasis: A population-based study.三阴性乳腺癌脑转移患者的预后预测和危险因素:一项基于人群的研究。
Cancer Med. 2023 Apr;12(7):7951-7961. doi: 10.1002/cam4.5575. Epub 2023 Jan 11.
6
Brain metastasis as the first and only metastatic relapse site portends worse survival in patients with advanced HER2 + breast cancer.脑转移作为首个也是唯一的转移复发部位,预示着晚期HER2阳性乳腺癌患者的生存期更差。
Breast Cancer Res Treat. 2023 Jan;197(2):425-434. doi: 10.1007/s10549-022-06799-7. Epub 2022 Nov 20.
7
Interactive effects of molecular subtypes with tumor size and extracranial metastatic pattern on risk of brain metastasis in breast cancer patients: A population-based study.基于人群的研究:分子亚型与肿瘤大小和颅外转移模式的相互作用对乳腺癌患者脑转移风险的影响。
Cancer Med. 2023 Mar;12(6):6547-6557. doi: 10.1002/cam4.5425. Epub 2022 Nov 9.
8
Prediction of Short and Long Survival after Surgery for Breast Cancer Brain Metastases.乳腺癌脑转移手术后短期和长期生存的预测
Cancers (Basel). 2022 Mar 10;14(6):1437. doi: 10.3390/cancers14061437.
9
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.曲妥珠单抗联合卡培他滨治疗人表皮生长因子受体 2(HER2)阳性转移性乳腺癌的多中心、随机、双盲、安慰剂对照、Ⅲ期临床研究(TRIO-1302/HER2CLIMB):脑转移亚组分析
Ann Oncol. 2022 Mar;33(3):321-329. doi: 10.1016/j.annonc.2021.12.005. Epub 2021 Dec 23.
10
NCCBM, a Nomogram Prognostic Model in Breast Cancer Patients With Brain Metastasis.NCCBM,一种用于乳腺癌脑转移患者的列线图预后模型。
Front Oncol. 2021 Apr 29;11:642677. doi: 10.3389/fonc.2021.642677. eCollection 2021.